TH — Theratechnologies Share News
0.000.00%
- CA$205.53m
- CA$252.52m
- $85.87m
Brief: Theratechnologies Reports Financial Results For Q3 2022
Brief: Theratechnologies Presents Data Demonstrating High Expression Of Sortilin (Sort1) In Multiple Tumor Types At 34Th Eortc-Nci-Aacr Symposium
Theratechnologies rises after FDA nod for HIV treatment's IV use
Brief: Theratechnologies To Announce Third Quarter 2022 Financial Results And Provide Business Update
Brief: Theratechnologies TH1902 Study Published In Pharmaceutics Shows Inhibition Of Human Sortilin (Sort1)-Positive Ovarian And Triple-Negative Breast Cancer Stem-Like Cells And Tumor Growth
Canada Research Roundup: Cargojet, Teck Resources, Valens Company
Brief: Theratechnologies Provides Update On Dose Escalation Portion Of Fast Track Designated TH1902 First-In-Human Study In Advanced Resistant Malignancies
Brief: Theratechnologies Raises Term Loan Of Up To $100 Million From Marathon Asset Management
Brief: Theratechnologies Initiates Basket Portion Of Th1902 First-In-Human Study In Advanced Resistant Malignancies
Brief: Theratechnologies to Focus Its Commercialization Activities on North American Territory
Brief: Theratechnologies Reports Financial Results For Q1 Fiscal 2022
Brief: Theratechnologies Reports Results From Trogarzo IV Push Administration Study at CROI 2022
Brief: Theratechnologies Submits Supplemental Biologics License Application To FDA Advancing Development Of Iv Push Trogarzo® For Patients Living With Hiv
Brief: Theratechnologies Announces Renewal Of Shelf Prospectus And Registration Statement At-The-Market Facility To Be Extended
Brief: Theratechnologies Q3 Sales Rose 27 Percent
Canada Stocks: Toronto futures rise on firmer gold prices
Brief: Theratechnologies Reports Positive Results for Trogarzo IV Push Administration Study
Brief: Theratechnologies Reports Q2 Results
Brief: Theratechnologies Announces New Preclinical Findings For Its Lead Investigational Peptide-Drug Conjugate Th1902 For The Potential Treatment Of Metastatic Cancers